Assessment of the immunoexpression profile of breast ductal carcinoma with Cyclin D1, Her-2/Neu and p53 at Yangon General Hospital, Myanmar

Authors

  • Khin Darli Tun Department of Pathology, Faculty of Medicine, MAHSA University, Malaysia
  • Min Ko Ko Department of Population and Family Health, University of Public Health (Yangon), Myanmar
  • Sudha Arumugam Department of Pathology, Faculty of Medicine, MAHSA University, Malaysia
  • Srikumar Chakravarthi Department of Pathology, Faculty of Medicine, MAHSA University, Malaysia
  • Jaya Vejayan Department of Biotechnology, University Malaysia Pahang, Malaysia

DOI:

https://doi.org/10.3126/njc.v5i1.41403

Keywords:

invasive ductal carcinoma Breast, CyclinD1, p53, Her2/neu

Abstract

One hundred cases of histologically proven invasive ductal carcinomas were histologically graded based on modified Bloom and Richardson Grading. Out of these 17 cases each of low grade, intermediate grade, and high grade invasive ductal carcinomas were selected for Immunostaining using the monoclonal antibodies Cyclin D1,pP53 and Her2/neu. It was found that for all three monoclonal antibodies the lowest histological grade of Invasive Ductal Carcinoma of the Breast showed the lowest positivity with Cyclin D1 ( 11.76%) and p53 ( 17.64%) and Her2/neu ( 47.05%). The intermediate grade tumour showed ( 70.58% ) positivity with Cyclin D1 and 58.58 % in p53 and Her2/neu. The high grade invasive ductal carcinoma of the breast showed the highest positivity of Cyclin D1 (76.47%) , p53 (88.24% ) ,Her2/neu ( 94.12% ); These suggest that Cyclin D1 , P53 and Her2/neuimmunoexpression positivity increases with rising histological grades of invasive ductal carcinoma of breast. 

Downloads

Download data is not yet available.
Abstract
106
PDF
110

Downloads

Published

2021-09-17

How to Cite

Tun, K. D., Ko, . M. K., Arumugam, S., Chakravarthi, S., & Vejayan, J. (2021). Assessment of the immunoexpression profile of breast ductal carcinoma with Cyclin D1, Her-2/Neu and p53 at Yangon General Hospital, Myanmar. Nepalese Journal of Cancer, 5(1), 44–49. https://doi.org/10.3126/njc.v5i1.41403

Issue

Vol. 5 No. 1 (2021)

Section

Original Articles

License

Copyright (c) 2021 Nepalese Journal of Cancer

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as NJC and the authors are acknowledged.

Submission of the manuscript means that the authors agree to assign exclusive copyright to NJC. The aim of NJC is to increase the visibility and ease of use of open access scientific and scholarly articles thereby promoting their increased usage and impact.